Latest Shareholder Value News

L1 Long Short Fund Limited reports robust investment returns well above the ASX200 benchmark and announces a shift to quarterly dividends starting December 2025, signaling confidence in sustained growth.

Commonwealth Bank of Australia reported a 2% increase in cash NPAT to approximately $2.6 billion for 1Q26, supported by lending and deposit growth despite margin pressures and rising expenses.

Altair Minerals has raised A$13 million through an institutional placement led by 1832 Asset Management, fully funding an extensive drilling program at its Greater Oko Project set to begin early next year.

Aureka Limited has sold its interest in the Tandarra Joint Venture for $1.3 million, settling related court disputes and redirecting funds to advance drilling at its promising Irvine Gold Project.

NRW Holdings showcased strong FY25 proforma results and ambitious FY26 guidance at the UBS Conference, underpinned by strategic acquisitions and a diversified portfolio. The company’s growth strategy focuses on expanding capabilities in energy transition and infrastructure markets across Australia, New Zealand, and North America.

Iress launches a comprehensive FY26 business efficiency program targeting a 25% cash EBITDA margin, while narrowing its FY25 guidance and welcoming a new CEO.

Memphasys Limited has successfully raised over $1.1 million through a pro-rata entitlement offer to accelerate the commercialisation of its innovative Felix™ sperm selection system, targeting key regulatory approvals and market expansion.

Count Limited reported robust FY2025 growth with funds under management surpassing $5.1 billion and increased dividends, while advancing its acquisition strategy and embracing AI-driven efficiencies.

ANZ Group Holdings Limited has announced a final dividend of 83 cents per share, 70% franked, payable in multiple currencies with reinvestment plans available. Shareholders have until November 17 to make their election choices.

ANZ Group Holdings reported a 10% decline in cash profit for FY2025 despite an 8% rise in operating income, maintaining its dividend amid significant restructuring and regulatory costs.

Epsilon Healthcare has posted its highest-ever quarterly receipts of $2.919 million, reflecting a robust turnaround since exiting voluntary administration in mid-2024. The company’s strategic sale and leaseback deal has also enabled significant debt reduction, setting the stage for sustained growth.

Epsilon Healthcare reports a strong rebound with a 73% revenue increase in the June quarter, driven by contract manufacturing and new pharmacy operations. The company is emerging from restructuring with renewed financial strength and growth prospects.